Argus
•
Sep 02, 2026
PTGX: Lowering target price to $154.00
Summary
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
KRYS: Raising target price to $400.00
Sep 02, 2026
•
KRYS
RCUS: Lowering target price to $31.00
Sep 02, 2026
•
RCUS
Daily Spotlight: Value Versus Growth Investing
Aug 28, 2026
•
BMY
KRYS: Raising target price to $392.00
Aug 26, 2026
•
KRYS
RCUS: Raising target price to $33.00
Aug 26, 2026
•
RCUS
